The Tokyo-based company collaborates with Japanese and foreign entities, including academics and pharmaceutical companies, to research and develop cures for inflammatory diseases and cancer. Founded in 2012, IDAC Theranostics focuses on creating meaningful results for patients with unmet medical needs through its drug development efforts.